Efficacy and Safety of Vorapaxar as Approved for Clinical Use in the United States

BACKGROUND: Vorapaxar is a protease‐activated receptor‐1 antagonist approved by the U.S. Food and Drug Administration (FDA) for the reduction of thrombotic cardiovascular (CV) events in patients with a history of myocardial infarction (MI) and peripheral artery disease (PAD), without a previous stro...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Am Heart Assoc
Main Authors: Magnani, Giulia, Bonaca, Marc P., Braunwald, Eugene, Dalby, Anthony J., Fox, Keith A. A., Murphy, Sabina A., Nicolau, José Carlos, Oude Ophuis, Ton, Scirica, Benjamin M., Spinar, Jindrich, Theroux, Pierre, Morrow, David A.
Formato: Artigo
Idioma:Inglês
Publicado: Blackwell Publishing Ltd 2015
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4392433/
https://ncbi.nlm.nih.gov/pubmed/25792124
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/JAHA.114.001505
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares